Program
tenapanor
Also written as “Tenapanor”, “AZD1722” and “KHK7791”.
Its studies are mostly in Hyperphosphatemia · Constipation · Breast Feeding · Kidney Failure, Chronic · Renal Insufficiency, Chronic, led by 2 companies.
Drug pageTenapanor: every studyAll 37 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ardelyxits history only | 272 open or running | phase 4since Jun 14, 2019 | Apr 20, 2011 | Feb 26, 2027phase 3 · NCT07382167 |
| Kyowa Kirin | 70 open or running | phase 3since Feb 16, 2021 | Jan 29, 2019 | none ahead |
Also a collaborator on its studies: AstraZeneca.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Kyowa Kirin only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 29, 2019First study: phase 2 study in HyperphosphatemiaFirst studyNCT03831607 · 67 enrolled · Japan
- Mar 4, 20192 phase 2 studies in HyperphosphatemiaNCT03864458, NCT03864445
- Feb 16, 20214 phase 3 studies in HyperphosphatemiaNCT04771780, NCT04767581, NCT04766398 and 1 more
TargetBeta
“Sodium/hydrogen exchanger 3 inhibitor”ChEMBL 37, by rule
Studies
All 7 Kyowa Kirin leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04771780Hyperphosphatemia · Japan | 3 | Completed | Jun 27, 2022 | 213 |
| NCT04767581Hyperphosphatemia · Japan | 3 | Completed | Aug 10, 2021 | 165 |
| NCT04766398Hyperphosphatemia · Japan | 3 | Completed | Sep 27, 2021 | 169 |
| NCT04766385Hyperphosphatemia · Japan | 3 | Completed | Dec 1, 2021 | 54 |
| NCT03864458Hyperphosphatemia · Japan | 2 | Completed | Dec 10, 2019 | 207 |
| NCT03864445Hyperphosphatemia · Japan | 2 | Completed | Dec 3, 2019 | 47 |
| NCT03831607Hyperphosphatemia · Japan | 2 | Completed | Nov 26, 2019 | 67 |
How it is read
Names in the registry
- “Tenapanor”, 11 entries
- “AZD1722”, 8 entries
- “KHK7791”, 7 entries
- “RDX5791”, 3 entries
- “Tenapanor 50 MG”, 1 entry
Codes read as this program: AZD1722.
Conditions, from the studies’ own filings
- Hyperphosphatemia, 13 studies
- Constipation, 9 studies
- Breast Feeding, 1 study
- Kidney Failure, Chronic, 1 study
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.